Gemtuzumab Ozogamicin (GO) + Chemotherapy
Treatment for Acute Myeloid Leukemia
Typical Dosage: 3 mg/m² IV on Days 1, 4, 7 of induction (fractionated), or single dose
Effectiveness
76%
Safety Score
30%
Clinical Trials
21
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
30
DangerousModerateSafe
Treatment Details
Dosage Range
3 mg/m² IV on Days 1, 4, 7 of induction (fractionated), or single dose
Time to Effect
Starts with chemotherapy, effects seen with improved EFS/OS
Treatment Duration
Given during induction and/or consolidation
Evidence Quality
HIGHNumber Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$65,000
Monitoring:$150,000
Side Effect Mgmt:$75,000
Total Annual:$290,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$50,000/QALY
QALYs Gained
2.7
Outcome-Based Costs
Cost per Responder
$414,286
Cost per Remission
$414,286
Comparison vs 7+3 Chemotherapy
Cost Difference
+$60,000/year
More expensive
QALY Difference
+0.30 QALYs
Better outcomes
Dominance
No dominance
Gemtuzumab Ozogamicin (GO) + Chemotherapy Outcomes
for Acute Myeloid Leukemia
Efficacy Outcomes
Overall Effectiveness
+76%
Response Rate
+70%
Remission Rate
+70%
Common Side Effects
Myelosuppression
+100%
Febrile neutropenia
+65%
Veno-occlusive disease (VOD)/SOS
+7%
Infusion-related reactions
+25%
Hemorrhage
+45%
Nausea/Vomiting
+45%
Active Clinical Trials
5 active trials recruiting for Gemtuzumab Ozogamicin (GO) + Chemotherapy in Acute Myeloid Leukemia
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
NCT04385290RECRUITINGPHASE1, PHASE2
214 participants
INTERVENTIONAL
München, Germany +20 more
Started: Sep 4, 2020
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
NCT04050280RECRUITINGPHASE2
39 participants
INTERVENTIONAL
Baltimore, United States
Started: Nov 1, 2019
Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML
NCT05662904NOT YET RECRUITINGPHASE1
12 participants
INTERVENTIONAL
Dresden, Germany +1 more
Started: Jan 1, 2028
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
NCT04777916RECRUITING
5K participants
OBSERVATIONAL
Amiens, France +29 more
Started: Apr 14, 2022
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
NCT04293562RECRUITINGPHASE3
1.4K participants
INTERVENTIONAL
Birmingham, United States +205 more
Started: Jul 21, 2020
Completed Clinical Trials
11 completed trials for Gemtuzumab Ozogamicin (GO) + Chemotherapy in Acute Myeloid Leukemia
Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia
NCT04915612COMPLETEDPHASE1
1 participants
INTERVENTIONAL
Houston, United States
Started: May 21, 2021
Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)
NCT03568994COMPLETEDEARLY_PHASE1
26 participants
INTERVENTIONAL
Baltimore, United States +1 more
Started: Jul 10, 2018
A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
NCT00927498COMPLETEDPHASE3
280 participants
INTERVENTIONAL
Argenteuil, France +18 more
Started: Dec 1, 2007
Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4
NCT02473146COMPLETEDPHASE2, PHASE3
225 participants
INTERVENTIONAL
Amiens, France +20 more
Started: Nov 18, 2015
Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation
NCT00893399COMPLETEDPHASE3
600 participants
INTERVENTIONAL
Graz, Austria +59 more
Started: May 12, 2010
A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia
NCT00233909COMPLETEDPHASE1, PHASE2
55 participants
INTERVENTIONAL
Started: Oct 1, 2005
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia
NCT00052299COMPLETEDPHASE3
472 participants
INTERVENTIONAL
Linz, Austria +54 more
Started: Sep 1, 2002
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia
NCT00049517COMPLETEDPHASE3
657 participants
INTERVENTIONAL
Birmingham, United States +98 more
Started: Dec 19, 2002
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
NCT00551460COMPLETEDPHASE2
78 participants
INTERVENTIONAL
Roseville, United States +191 more
Started: Nov 15, 2007
Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome
NCT03672539COMPLETEDPHASE2
50 participants
INTERVENTIONAL
Houston, United States
Started: Nov 7, 2018
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
NCT03226418COMPLETEDPHASE2
75 participants
INTERVENTIONAL
Omaha, United States
Started: Jul 7, 2017
Showing 20 of 21 total trials